Bacil Pharma (524516) Q4 24/25 earnings summary

Executive summary

• Audited financial results for the quarter and year ended March 31, 2025, were approved by the Board and received an unmodified audit opinion.

• Financial statements prepared in accordance with Ind AS and SEBI regulations, with no separate reportable segments.

Financial highlights

• Total revenue for FY25 was ₹66.14 lakhs, up from ₹13.05 lakhs in FY24; Q4 revenue was ₹8.77 lakhs.

• Net profit for FY25 was ₹40.05 lakhs, compared to a net profit of ₹11.38 lakhs in FY24.

• Q4 FY25 profit before tax was ₹1.56 lakhs, compared to a loss of ₹4.05 lakhs in Q4 FY24.

• EPS for FY25 was ₹0.69, compared to a loss per share of ₹0.10 in FY24.

• Other comprehensive income for FY25 was a loss of ₹0.36 lakhs, compared to a gain of ₹17.28 lakhs in FY24.

Outlook and guidance

• Financial statements prepared on a going concern basis; no indication of intent to liquidate or cease operations.